NAGIOS: RODERIC FUNCIONANDO

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain

dc.contributor.author	Conget, Ignacio
dc.contributor.author	Mauricio, Dídac
dc.contributor.author	Ortega, Rafael
dc.contributor.author	Detournay, Bruno
dc.contributor.author	Muros, Teresa
dc.contributor.author	De la Cuesta, Carmen
dc.contributor.author	Mangas Cruz, Miguel Ángel
dc.contributor.author	Hernández Herrero, Cristina
dc.contributor.author	De Castro Hernández, Paloma
dc.contributor.author	Gómez Peralta, Fernando
dc.contributor.author	Miralles García, José Manuel
dc.contributor.author	Martínez, Encarna
dc.contributor.author	Cuatrecasas, Guillem
dc.contributor.author	Aguilera, Eva
dc.contributor.author	Giménez, Margarita
dc.contributor.author	Vinagre, Irene
dc.contributor.author	Anglada, Jordi
dc.contributor.author	Pérez Maraver, Manuel
dc.contributor.author	Manzanares, Jose María
dc.contributor.author	Fernández Catalina, Pablo
dc.contributor.author	Bellido Guerrero, Diego
dc.contributor.author	Soto González, Alfonso
dc.contributor.author	Casanueva, Felipe
dc.contributor.author	Masmiquel, Lluís
dc.contributor.author	Gómez, Luis Alberto
dc.contributor.author	García, Honorato
dc.contributor.author	Arguelles, Iñaqui
dc.contributor.author	Garcia Puig, Juan
dc.contributor.author	Brito Sanfiel, Miguel Ángel
dc.contributor.author	Escalada, Francisco Javier
dc.contributor.author	Gaztambide, Sonia
dc.contributor.author	Hernández Mijares, Antonio
dc.contributor.author	Ampudia Blasco, Francisco Javier
dc.contributor.author	Tréscoli, Carlos
dc.contributor.author	Merino Torres, Juan Francisco
dc.contributor.author	De Teresa Parreño, Luis
dc.date.accessioned	2019-02-25T09:24:42Z
dc.date.available	2019-02-25T09:24:42Z
dc.date.issued	2016
dc.identifier.citation	Conget, Ignacio Mauricio, Dídac Ortega, Rafael Detournay, Bruno Muros, Teresa De la Cuesta, Carmen Mangas Cruz, Miguel Ángel Hernández Herrero, Cristina De Castro Hernández, Paloma Gómez Peralta, Fernando Miralles García, José Manuel Martínez, Encarna Cuatrecasas, Guillem Aguilera, Eva Giménez, Margarita Vinagre, Irene Anglada, Jordi Pérez Maraver, Manuel Manzanares, Jose María Fernández Catalina, Pablo Bellido Guerrero, Diego Soto González, Alfonso Casanueva, Felipe Masmiquel, Lluís Gómez, Luis Alberto García, Honorato Arguelles, Iñaqui Garcia Puig, Juan Brito Sanfiel, Miguel Ángel Escalada, Francisco Javier Gaztambide, Sonia Hernández Mijares, Antonio Ampudia Blasco, Francisco Javier Tréscoli, Carlos Merino-Torres, Juan Francisco De Teresa Parreño, Luis 2016 Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain Bmj Open 6 e010197
dc.identifier.uri	http://hdl.handle.net/10550/69173
dc.description.abstract	Objective: Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment. There are no published data on the clinical and sociodemographic profile of patients initiating treatment with GLP-1Ra in Spain. Our objective was to understand these patients' characteristics in a real-world clinical practice setting. Design: Cross-sectional observational study. Setting: Spanish specialist outpatient clinics. Participants: 403 adults with DM2 initiating GLP-1Ra treatment were included. Primary and secondary outcome measures: Sociodemographic and DM2-related clinical data, including treatment at and after GLP-1Ra initiation and comorbidities, were collected. Results: Evaluable patients (n=403; 50.9% female) were included ( July 2013 to March 2014) at 24 centres by 53 specialists (47 endocrinology, 6 internal medicine), with the following profile (value±SD): age (58.3±10.4 years), diabetes duration (9.9±7 years), body mass index (BMI; 36.2±5.5) and glycated haemoglobin (HbA1c; 8.4±1.4%); 14% had HbA1c≤7%. Previous antidiabetic treatment: 53.8% only oral antidiabetic drugs (OADs), 5.2% insulin and 40% insulin and OAD; of those receiving OAD, 35% single drug, 38.2% 2 drugs and 24% 3 drugs. Concomitant to GLP-1Ra, 55.3% were only on OAD, 36.2% on insulin and OAD, and 7.2% only on insulin. Of those receiving OAD, the GLP-1Ra was mainly associated with 1 drug (65%) or 2 drugs (31.8%). GLP-1Ra are frequently added to existing antidiabetic drugs, with dipeptidyl peptidase-4 inhibitors being the OAD most frequently switched (45% receiving 1 before starting GLP-1Ra, only 2.7% receiving it concomitantly). Conclusions: In Spain, GLP-1Ra therapy is usually started in combination with OADs or OADs and insulin. These drugs are used in relatively young patients often not reaching therapeutic goals with other treatment combinations, roughly a decade after diagnosis and with a relatively high BMI. The latter could be explained
dc.language.iso	eng
dc.relation.ispartof	Bmj Open, 2016, vol. 6, p. e010197
dc.subject	Malalties d'origen nutricional
dc.title	Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain
dc.type	journal article	es_ES
dc.date.updated	2019-02-25T09:24:42Z
dc.identifier.doi	10.1136/bmjopen-2015-010197
dc.identifier.idgrec	114002
dc.rights.accessRights	open access	es_ES